Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-1819 injection receives notification of approval for drug clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received the approval notification for clinical trial of SHR-1819 injection from the National Medical Products Administration (NMPA) and will soon begin clinical trials. It is reported that SHR-1819 injection is a recombinant humanized monoclonal antibody targeting human IL-4R independently developed by the company, which can simultaneously block the signaling of IL-4 and IL-13 and is intended for the treatment of type 2 inflammation-related diseases.